A month af­ter mul­ti-bil­lion dol­lar No­var­tis deal, BeiGene fol­lows up with 're­verse' deal

Just over a month af­ter strik­ing a deal with No­var­tis to bring its PD-1 an­ti­body tislelizum­ab state­side, Chi­na-based BeiGene is mak­ing a sim­i­lar play in re­verse.

On Wednes­day evening, BeiGene took the wraps off a $120 mil­lion-plus deal with Boston Im­mune Tech­nolo­gies and Ther­a­peu­tics to de­vel­op and com­mer­cial­ize their tu­mor necro­sis fac­tor re­cep­tor 2 (TN­FR2) an­tag­o­nist an­ti­bod­ies in Asia (ex­clud­ing Japan), Aus­tralia and New Zealand.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER